All In Biotech

Drug Trial Radar · NCT06576843

INDV-6001 Multiple-Dose Pharmacokinetic Study

An Open-label, Multicentre Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Repeated Doses of INDV-6001 in Adults With Moderate to Severe Opioid Use Disorder

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

123

Actual

Start

Sep 17, 2024

Primary completion

Jan 21, 2026

Study completion Jan 21, 2026

Sponsor

Lead sponsor
Indivior Inc.Industry
Sponsor type
Industry
First posted
Aug 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, open-label, multiple dose study of INDV-6001 in adult participants with moderate or severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). The current study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmucosal (TM) BUP (SUBOXONE®) or will transition from a 100-mg monthly maintenance dose of SC extended-release BUP (SUBLOCADE®). This study will also evaluate the use of alternative injection sites (thigh, back of upper arm), which may be desirable in this patient population for the anticipated extended durations of treatment.

Conditions

  • Moderate to Severe Opioid Use Disorder

Interventions

  • INDV-6001Drug

    Extended-release subcutaneous injection

  • SuboxoneDrug

    Oral sublingual film

  • SublocadeDrug

    Extended-release subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
  2. Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
  3. Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
  4. Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
  5. Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
  6. Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
  7. Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injectionTime frame: Up to 260 days
  8. Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
  9. Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
  10. Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
  11. Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
  12. Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
  13. Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
  14. Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
  15. Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
  16. Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
  17. Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
  18. Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
  19. Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
  20. Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
  21. Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Artemis Institute for Clinical Research

    San Diego, California

  • Innovative Clinical Research, Inc.

    Miami Lakes, Florida

  • Chicago Clinical Research Institute Inc.

    Chicago, Illinois

  • Precise Research Centers

    Flowood, Mississippi

  • Hassman Research Institute (Cenexel HRI - Marlton)

    Marlton, New Jersey

  • Richmond Behavioral Associates

    Staten Island, New York

  • Midwest Clinical Research

    Dayton, Ohio

  • Insite Clinical Research, LLC

    DeSoto, Texas

  • Memorial Hermann Village

    Houston, Texas

  • Pillar Clinical Research

    Richardson, Texas

  • Progressive Clinical Research

    Bountiful, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.